Routine immunization consultants (RICON) review in Nigeria: A country driven management approach for health systems strengthening in routine immunization

M. O’Connell, C. Woolody; Johns Hopkins International Vaccine Access Center, Baltimore, MD/US

Background: Since 2006 the Nigerian government has deployed Routine Immunization (RI) Consultants to all 36 states and the Federal Capital Territory to serve as technical assistance (TA) for RI. To date, there has been no systematic evaluation of the consultant program. Here we review this country driven management approach to TA in order to provide recommendations to inform future strategies.

Methods: We conducted a retrospective programmatic review from Jun-Sept 2014 using qualitative and quantitative methods. In total, 84 qualitative interviews with 101 participants were recorded. Recorded data was complete and high quality for 70 of these interviews, thus qualitative data analysis was conducted on 70 in-depth interviews and focus group discussions with a total of 82 individuals from 7 States and the FCT in Nigeria. Respondents were purposively drawn from national, state, and local government levels. Additionally, an online survey was sent to 89 respondents across all states. All qualitative interviews were audio-recorded, transcribed verbatim, hand-coded and analyzed using Atlas.ti software. This study was approved by the JHSPH IRB and the NHREC of Nigeria.

Findings: The majority of respondents were male (66%, n=67) with an average age of 50 ± 5.6yrs (range 33-67yrs). According to their TORs, RI consultants are required to play a role in advocacy, technical assistance, supportive supervision, M&E, and capacity building. Overall, RI Consultants were inconsistently deployed across states. Currently only 23 of 36 States and the FCT have an active RI Consultant. State level respondents considered advocacy and supportive supervision as the consultant’s most important roles. RI Consultants activities were generally well aligned with their TORs although gaps were found in their ability to monitor state use of RI funds. In three of seven states, Consultants were well integrated as members of the State RI teams. Those not integrated addressed through non-structured interviews with nine hospital-based pharmacists in Phase 3. Results from the different phases were converged during the interpretation phase. Phase 1 survey results were compared to themes identified from observations (Phase 2) and interviews (Phase 3) to confirm actual PTC structure and activities. Ethical clearance was obtained from Meduna School Research and Ethics Committee and permission granted by provincial authorities.

Findings: The results showed that most professionals were represented in the PTCs, with variations according to hospital level of care. Membership of all PTCs included a pharmacist, who in the majority of cases fulfilled the secretariat position. Most of the PTCs conducted meetings at least once/month. Main PTC activities included dissemination of decisions (100%) and formulary management (89.5%). Reporting of adverse drug reactions (ADRs) and medication errors PTC function was poor at all levels. Lack of expertise in pharmaco economics and evidence-based decision-making was identified as one of the challenges in formulary management. Survey results and interviews with pharmacists revealed that insufficient staff and poor attendance of meetings hindered PTC activities.

Interpretation: Lack of expertise on the application of pharmaco economic analysis and evidence-based decision-making in formulary management, and limited ADR reporting in attaining rational medicines use at all levels, were identified as the main challenges in the activities of the PTCs. Future programmes should strengthen PTCs in specialised aspects of formulary management, and further training in the principles of pharmacovigilance is required to enhance ADR reporting, as well as to ensure compliance with both WHO and provincial guidelines. Strong institutional support of PTCs should be encouraged in order to ensure better participation of staff in PTC activities to guarantee rational medicines use in public sector hospitals in Gauteng Province.

Funding: Self funded.

Abstract #: 02GMHE006

Selecting essential medicines: How economic data are used throughout the WHO decision making process

C. Moucherad1, V. Wirtz2, C. Curnyn3, M.R. Reich1; 1Harvard School of Public Health, Boston, MA/US; 2Department of Global Health/Center for Global Health and Development, Boston University, Boston, MA/US; 3Boston University School of Public Health, Boston, MA/US

Background: For the past decade, the World Health Organization has strengthened its evidence-based process to make decisions about which products are added to the global Essential Medicines List (EML). The EML identifies high-quality and reasonable-cost medicines that address priority health needs, and over 155 countries have adapted this list for their own national EMLs. The EML is an important tool for global governance, and decisions about additions have a major impact on global and national decisions, with significant budgetary, ethical and health implications. The objective of this study is to analyze the quality of publicly available economic evidence in applications for and decisions about addition to the EML.

Methods: The paper analyzes price data and economic evaluation data presented in applications, the assessment of this information by reviewers of the application and how these two sources of information were used in making EML decisions. The sample includes 134 applications for additions to the WHO adult EML, from 2002 to 2013 (available on the WHO website) and 177 reviews of applications. The key variables of interest included provision of price and/or cost-effectiveness information within the application; discussion of these economic data by expert reviewers; and the WHO Committee’s decision about whether to add each medicine to the list.

Findings: This analysis found significant deficiencies in the provision of required economic data in new applications to the EML: only 6% of 134 applications included complete price data and economic evaluation data, and many omitted or misinterpreted the economic evaluation section entirely (57.5% and 17.9%, respectively). Similarly, only 36% of reviewers mentioned price information and 22% mentioned economic evaluation. Despite the high degree of data incompleteness in the studied applications, all were reviewed by the Committee; and there was no statistically significant association between completeness of information and likelihood of addition to the EML. Qualitative analysis indicates that the WHO tries to address information gaps in applications by conducting its own review and analysis.

Interpretation: This is the first comprehensive analysis of the use of economic data in the EML decision process; it examines applications, recommendations and decisions across all medicine types and over a period of 12 years. The results suggest that improvements could be made to increase the transparency and efficiency of the EML application process; applicants should be encouraged, and perhaps required, to submit high-quality and complete applications, which includes economic data (or explicit mention of a lack thereof). Additionally, WHO should provide explicit rules and methods for how economic data are used in decision making for the EML and the consequences of not including required data.

Funding: No source of funding was received for this research. 

Abstract #: 02GMHE006

Annals of Global Health